GRAIL, LLC(GRAL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
3-STAR RATING
PASS
LAST CLOSE
$115.89
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for GRAL

11/13/2026: GRAL (3-star) is currently NOT-A-BUY. Pass it for now.

GRAIL, LLC is a commercial-stage healthcare company specializing in multi-cancer early detection via its flagship Galleri blood test. The company's primary strength lies in its pioneering methylation technology and extensive clinical validation data, offering a disruptive growth story in preventative oncology. However, key risks include heavy net operating losses, ongoing cash burn, and the challenge of securing broad insurance reimbursement. The stock best suits growth-oriented investors with high risk tolerance who are willing to monitor regulatory progress, test adoption rates, and clinical developments over the long term.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitGRAIL offers high top-line revenue expansion and exposure to disruptive early-stage cancer screening markets.
Momentum investorStrong fit while signal remains positiveThe stock experiences notable price momentum driven by clinical updates and market enthusiasm for liquid biopsies.
Value investorWeak fitThe company lacks earnings and trades at negative net margins with high ongoing cash burn.
Dividend investorWeak fitGRAIL does not pay dividends and retains all earnings to fund research and commercial scaling.
Low-risk investorWeak fitHigh price volatility, regulatory uncertainties, and lack of profitability expose risk-averse investors to substantial downside.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences sharp price swings reacting to clinical trial readouts, market sentiment, and healthcare sector trends.
Valuation riskMedium / highValuing a pre-profitability genomic pioneer relies heavily on long-term adoption assumptions rather than near-term earnings.
Competition risk (liquid biopsy and multi-cancer screening competition)HighRivals like Guardant Health and Natera are aggressively developing competing oncology screening tools.
Business qualityMediumProprietary scientific assets are world-class, but commercialization infrastructure and payer coverage remain works in progress.
Dividend incomeLow / noneIncome-focused investors receive zero cash returns from dividend payouts.
Execution riskHighSuccess depends heavily on scaling test volume, securing broad insurance reimbursement, and executing regulatory strategies.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.21B USD
Price to earnings Ratio -
1Y Target Price 139.44
Price to earnings Ratio -
1Y Target Price 139.44
Volume (30-day avg) 952.2K shares
Beta 2.87
52 Weeks Range 41.50 - 166.47
Updated Date 11/15/2026
52 Weeks Range 41.50 - 166.47
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -9.22

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
68.8%
Active BUY / eligible
11 / 16
30-Day BUY Count Change
0

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Hockey-Stick Growth
PRICE PATH

Hockey-Stick Growth

The stock demonstrates a Hockey-Stick Growth price path pattern.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 481.44%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
GRAL receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
GRAL has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+79.9%) and solid revenue growth (+17.2%) are partially offset by weak cash generation (FCF margin -203.8%), weak profitability (net margin -277.5%).

Financial Health Rating

★★★★★
GRAL's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 29.9%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is GRAL's strongest growth driver at +79.9% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+17.2%, solid) and free-cash-flow growth (+48.5%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 86.2% and approximately 77.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 5.06% supports management-shareholder alignment.

Top 5 Institutional Investors

Farallon Capital Management, L.L.C. 9.30%
Baker Bros Advisors LP 9.00%
BlackRock Inc 7.99%
Fort Hoosac Management, LLC 6.93%
State Street Corp 5.33%

Unit Economics (Per $1K Revenue)

★★★★★
GRAL generates approximately $-425 of gross profit, $-3,630 of operating income, and $-2,038 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 23.60%

Quantitative Style Profile

★★★★★
GRAL has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Multi-Cancer Early Detection TestingCommercial laboratory processing and analysis fees generated from the Galleri blood screening test ordered by physicians.The company primarily earns revenue each time a patient takes its proprietary blood test to screen for hidden cancers.
Research and Development ServicesCollaborative clinical development programs and genomic sequencing services provided to biopharmaceutical partners.Secondary income is derived from scientific partnerships and clinical validation research projects.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 1.11
Enterprise Value 4.51B
Price to Sales(TTM) 31.28
Enterprise Value 4.51B
Price to Sales(TTM) 31.28
Enterprise Value to Revenue 27.06
Enterprise Value to EBITDA -
Shares Outstanding 44.96M
Shares Floating 34.64M
Shares Outstanding 44.96M
Shares Floating 34.64M
Percent Insiders 5.06
Percent Institutions 86.22

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.